Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL

Recruiting now · Phase 1/Phase 2

Conditions studied: Relapse/Refractory B-cell Acute Lymphoblastic Leukemia

In brief

The goal of this clinical trial is to evaluate the safety and efficacy of CD19 CAR-T cells in pediatric patients of all genders, aged 2 to 18 years, with relapsing or refractory B cell acute lymphoblastic leukemia (r/r B-ALL). The main questions it aims to answer are as following: 1. What is the percentage of patients with overall remission rate (ORR) of complete response (CR) or complete remission with incomplete blood count recovery (CRi)? 2. What is the rate of Event-free survival at first month and 2-3 months after intervention? 3. What is the rate of Overall survival at first month and at 3 months after the intervention?

Key facts

Study ID
NCT06635330
Run by
Kara Yakhteh Tajhiz Azma Company
People needed
5
Starts
2024-05-20
Expected to finish
2027-09-22
Last updated by the study team
2024-10-10

Who can join

Age: 2 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.